Abstract
Dapsone is indicated for a variety of conditions, both dermatologic and non-dermatologic. The FDA-approved indications are leprosy and dermatitis herpetiformis. The non-FDA-approved indications include a wide range of dermatoses and malaria and Pneumocystis (carinii) jiroveci prophylaxis and treatment. This activity reviews the mechanism of action, adverse event profile, toxicity, dosing, pharmacodynamics, and monitoring of dapsone, pertinent for interprofessional team members in treating conditions where dapsone is indicated.